Regencell Bioscience Holdings Limited (RGC)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| Operating profit | $m | -4 | -7 | ||||||
| Net profit | $m | -1 | -1 | -7 | -6 | -4 | -4 | -7 | - |
| EPS reported | $ | -0.01 | -0.01 | ||||||
| Operating cashflow per share | $ | -0.01 | -0.01 | ||||||
| Capex per share | $ | 0.00 | 0.00 | ||||||
| FCF per share | $ | -0.01 | -0.01 | ||||||
| Free cash flow | $m | -3 | -3 | ||||||
| Net debt | $m | -5 | -2 | ||||||
| Book value equity | $m | 5 | 1 | ||||||
| Book value per share | $ | 0.01 | 0.00 | ||||||
| Number of shares | m | 494.49 | 494.49 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 1,733.67 | 6,910.13 | ||||||
| P/S LTM | x | 0.00 | 0.00 | ||||||
| P/FCF LTM | x | -2,579.73 | -3,251.35 | ||||||
| EV/EBITDA LTM | x | -2,639.60 | -1,198.29 | ||||||
| EV/Sales LTM | x | 0.00 | 0.00 | ||||||
| Earnings Yield LTM | % | -0.04% | -0.26% | ||||||
| FCF Yield | % | -0.04% | -0.03% | ||||||
| Quality | |||||||||
| ROE | % | -73.75% | -231.87% | ||||||
| ROIC | % | -69.75% | -4.44% | ||||||
| Operating margin | % | 0.00% | 0.00% | ||||||
| Gross margin | % | 0.00% | 0.00% | ||||||
| FCF/Sales | % | - | - | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | - | - | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -6.00 | -6.71 | ||||||
| Net Debt/EBITDA | x | 0.59 | 0.28 | ||||||
| EBIT/Net interest | x | 0.00 | 0.00 | ||||||
| Net debt/market cap | % | +0.00% | +0.01% | ||||||
| Net debt/Equity | x | -0.94 | -1.62 | ||||||
| Gross debt/equity | x | 0.11 | 0.32 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Regencell Bioscience Holdings Limited is a biotechnology firm specializing in Traditional Chinese Medicine (TCM). Its core activities revolve around the research, development, and market introduction of TCM solutions specifically designed to address neurocognitive disorders and related degeneration. The company places a particular emphasis on conditions such as attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). Established in 2014, Regencell Bioscience maintains its primary office in Causeway Bay, Hong Kong.
Similar companies
- Harbin Pharmaceutical Group Co., Ltd.
- Hybio Pharmaceutical Co., Ltd.
- Tasly Pharmaceutical Group Co., Ltd
- Betta Pharmaceuticals Co., Ltd.
- Jilin Aodong Pharmaceutical Group Co., Ltd.
- Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited
- Guangdong Zhongsheng Pharmaceutical Co., Ltd.
- Neuland Laboratories Limited
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Regencell Bioscience Holdings Limited (RGC)
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Regencell Bioscience Holdings Limited is a biotechnology firm specializing in Traditional Chinese Medicine (TCM). Its core activities revolve around the research, development, and market introduction of TCM solutions specifically designed to address neurocognitive disorders and related degeneration. The company places a particular emphasis on conditions such as attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). Established in 2014, Regencell Bioscience maintains its primary office in Causeway Bay, Hong Kong.
- Harbin Pharmaceutical Group Co., Ltd.
- Hybio Pharmaceutical Co., Ltd.
- Tasly Pharmaceutical Group Co., Ltd
- Betta Pharmaceuticals Co., Ltd.
- Jilin Aodong Pharmaceutical Group Co., Ltd.
- Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited
- Guangdong Zhongsheng Pharmaceutical Co., Ltd.
- Neuland Laboratories Limited
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free